It is because of the absence of these documents that the manufacturers of nevirapine ‘ Boehringer-Ingelheim ‘ withdrew their application for registration of the drug for PMTCT use in the US. Currently, the sponsors of the HIVNET 012 study in Uganda – the National Institutes of Health ‘ have returned to that country in an effort to collate the missing documents. In this report, Khopotso Bodibe of Health-e News Service, attempts to piece together why the Uganda study is under review.
To obtain the audio file please contact the Editor.




